The first published randomised controlled trial of laser treatment for vaginal atrophy raises serious questions

Melissa J Buttini and Christopher Maher
Med J Aust 2018; 209 (9): . || doi: 10.5694/mja18.00187
Published online: 5 November 2018

We still await well conducted RCTs of CO2 laser therapy for vaginal atrophy; in the meantime, topical oestrogen therapy remains the gold standard

Vaginal laser therapy has entered the global marketplace promising women relief from symptoms of genitourinary syndrome of menopause (GSM), formerly known as vulvovaginal atrophy.

  • Melissa J Buttini1
  • Christopher Maher2

  • 1 The Wesley Hospital, Brisbane, QLD
  • 2 University of Queensland, Brisbane, QLD


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.